Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
CSF
0.00%
4.0¢
CATALANO SEAFOOD LTD - Charts / Financials
Currently unlisted.
Proposed listing date: 4 MARCH 2022 12:30PM AEDT ##
Add to my watchlist
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Day | ||||||||
---|---|---|---|---|---|---|---|---|
Open | 0.0¢ | Day High | 0.0¢ | Day Low | 0.0¢ | |||
Daily Volume | 0 |
Bids | Sellers | |||||
---|---|---|---|---|---|---|
Number | Price | Volume | Number | Price | Volume | |
0 | 0.0¢ | 0 | 0 | 0.0¢ | 0 |
Data source: Refinitiv